Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Transcell Biologics is a private Hyderabad-based Indian biotech focused on stem cell technologies, regenerative medicine, and human-relevant testing platforms. The company says it develops disruptive stem cell-based solutions for chronic and debilitating diseases, with work spanning cell-based therapies, biobanking, hematopoietic stem cell transplantation support, and drug/vaccine safety testing. Public descriptions indicate two internal regenerative medicine programs aimed at Alzheimer's disease and muscular dystrophies, alongside oncology-oriented drug discovery and human microphysiological systems offerings. More recently, the company has highlighted its Digital Animal Replacement Technology (DART), which combines human microphysiological systems with AI/ML-enabled in silico tools for animal-free safety and efficacy testing for biopharma customers. Overall, Transcell appears to operate as a hybrid therapeutics-and-platform company with stronger public visibility around stem cell applications and translational testing services than around named clinical assets.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Transcell Biologics.